Related Experiment Video
Updated: Jan 28, 2026

Profiling of Estrogen-regulated MicroRNAs in Breast Cancer Cells
Published on: February 21, 2014
Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in
Valentina Rossi1, Erika Di Zazzo1, Giovanni Galasso1
1Dipartimento di Medicina di Precisione, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy.
Abstract:
Prostate cancer (PC) is one of the most frequently diagnosed cancers and a leading cause of cancer-related deaths in Western society. Current PC therapies prevalently target the functions of androgen receptor (AR) and may only be effective within short time periods, beyond which the majority of PC patients progress to castration-resistant PC (CRPC) and metastatic disease. The role of estradiol/estradiol receptor (ER) axis in prostate transformation and PC progression is well established. Further, considerable efforts have been made to investigate the mechanism by which somatostatin (SST) and somatostatin receptors (SSTRs) influence PC growth and progression. A number of therapeutic strategies, such as the combination of SST analogs with other drugs, show, indeed, strong promise. However, the effect of the combined treatment of SST analogs and estradiol on proliferation, epithelial mesenchyme transition (EMT) and migration of normal- and cancer-derived prostate cells has not been investigated so far. We now report that estradiol plays anti-proliferative and pro-apoptotic effect in non-transformed EPN prostate cells, which express both ERα and ERβ. A weak apoptotic effect is observed in transformed CPEC cells that only express low levels of ERβ. Estradiol increases, mainly through ERα activation, the expression of SSTRs in EPN, but not CPEC cells. As such, the hormone enhances the anti-proliferative effect of the SST analog, pasireotide in EPN, but not CPEC cells. Estradiol does not induce EMT and the motility of EPN cells, while it promotes EMT and migration of CPEC cells. Addition of pasireotide does not significantly modify these responses. Altogether, our results suggest that pasireotide may be used, alone or in combination with other drugs, to limit the growth of prostate proliferative diseases, provided that both ER isoforms (α and β) are present. Further investigations are needed to better define the cross talk between estrogens and SSTRs as well as its role in PC.
Insights
Estradiol shows anti-proliferative effects on normal prostate cells by increasing somatostatin receptor sensitivity to pasireotide. However, it promotes cancer cell migration, highlighting the importance of estrogen receptor presence for effective prostate cancer therapies.
Area of Science:
- Oncology
- Endocrinology
- Cell Biology
Background:
- Prostate cancer (PC) therapies targeting androgen receptors often lead to castration-resistant PC (CRPC).
- The roles of estradiol/estradiol receptor (ER) and somatostatin/somatostatin receptors (SSTRs) in PC progression are recognized.
- The combined effects of SST analogs and estradiol on prostate cells remain largely unexplored.
Purpose of the Study:
- To investigate the impact of combined estradiol and SST analog (pasireotide) treatment on normal and cancer-derived prostate cells.
- To determine the influence of estradiol on proliferation, epithelial-mesenchymal transition (EMT), and migration in prostate cells.
- To assess how ER expression levels affect cellular responses to estradiol and pasireotide.
Main Methods:
- Treatment of normal (EPN) and cancer-derived (CPEC) prostate cells with estradiol and pasireotide.
- Analysis of cell proliferation, apoptosis, EMT markers, and cell migration.
- Assessment of ERα, ERβ, and SSTR expression levels via molecular techniques.
Main Results:
- Estradiol exhibited anti-proliferative and pro-apoptotic effects on EPN cells expressing ERα and ERβ.
- Estradiol promoted EMT and migration in CPEC cells with low ERβ expression.
- Estradiol enhanced pasireotide's anti-proliferative effect in EPN cells by increasing SSTR expression, mainly via ERα.
Conclusions:
- Pasireotide may be a valuable therapeutic agent for prostate proliferative diseases, especially when both ERα and ERβ are present.
- Estradiol's dual role—beneficial in normal cells, potentially detrimental in cancer cells—necessitates careful consideration in treatment strategies.
- Further research is required to elucidate the intricate crosstalk between estrogens and SSTRs in prostate cancer progression.
More Related Videos
09:07Detecting the Ligand-binding Domain Dimerization Activity of Estrogen Receptor Alpha Using the Mammalian Two-Hybrid Assay
Published on: December 19, 2018
07:42Imaging of Estrogen Receptor-α in Rat Pial Arterioles using a Digital Immunofluorescent Microscope
Published on: November 29, 2011
Related Concept Videos
Internal Receptors
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Types of Receptors: Cell Surface Receptors
Cell Specific Gene Expression
Cell Specific Gene Expression
Receptor-mediated Endocytosis